Literature DB >> 20298178

New models of neoplastic progression in Barrett's oesophagus.

Kirill Pavlov1, Carlo C Maley.   

Abstract

Research in Barrett's oesophagus, and neoplastic progression to OAC (oesophageal adenocarcinoma), is hobbled by the lack of good pre-clinical models that capture the evolutionary dynamics of Barrett's cell populations. Current models trade off tractability for realism. Computational models are perhaps the most tractable and can be used both to interpret data and to develop intuitions and hypotheses for neoplastic progression. Tissue culture models include squamous cell lines, Barrett's oesophagus cell lines and OAC cell lines, although it was recognized recently that BIC-1, SEG-1 and TE-7 are not true OAC cell lines. Some of the unrealistic aspects of the micro-environment in two-dimensional tissue culture may be overcome with the development of three-dimensional organotypic cultures of Barrett's oesophagus. The most realistic, but least tractable, model is a canine surgical model that generates reflux and leads to an intestinal metaplasia. Alternatively, rat surgical models have gained popularity and should be tested for the common genetic features of Barrett's oesophagus neoplastic progression in humans including loss of CDKN2A (cyclin-dependent kinase inhibitor 2A) and TP53 (tumour protein 53), generation of aneuploidy and realistic levels of genetic diversity. This last feature will be important for studying the effects of cancer-prevention interventions. In order to study the dynamics of progression and the effects of an experimental intervention, there is a need to follow animals longitudinally, with periodic endoscopic biopsies. This is now possible and represents an exciting opportunity for the future.

Entities:  

Mesh:

Year:  2010        PMID: 20298178      PMCID: PMC2866622          DOI: 10.1042/BST0380331

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  52 in total

Review 1.  Changing role of in vivo models in columnar-lined lower esophagus.

Authors:  Y Koak; M Winslet
Journal:  Dis Esophagus       Date:  2002       Impact factor: 3.429

2.  Crypt dynamics and colorectal cancer: advances in mathematical modelling.

Authors:  I M M van Leeuwen; H M Byrne; O E Jensen; J R King
Journal:  Cell Prolif       Date:  2006-06       Impact factor: 6.831

3.  beta-Carotene and the role of intervention studies.

Authors:  J D Potter
Journal:  Cancer Lett       Date:  1997-03-19       Impact factor: 8.679

Review 4.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

Review 5.  Reflux injury of esophageal mucosa: experimental studies in animal models of esophagitis, Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Yan Li; Robert C G Martin
Journal:  Dis Esophagus       Date:  2007       Impact factor: 3.429

6.  Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line.

Authors:  Hector Alvarez; Jan-Bart M Koorstra; Seung-Mo Hong; Jurjen J Boonstra; Winand N M Dinjens; Arlene A Foratiere; Tsung-Teh Wu; Elizabeth Montgomery; James R Eshleman; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2008-11-04       Impact factor: 4.742

Review 7.  Barrett's esophagus, dysplasia, and adenocarcinoma.

Authors:  R C Haggitt
Journal:  Hum Pathol       Date:  1994-10       Impact factor: 3.466

8.  Thrombospondin-1 is a major activator of TGF-beta1 in vivo.

Authors:  S E Crawford; V Stellmach; J E Murphy-Ullrich; S M Ribeiro; J Lawler; R O Hynes; G P Boivin; N Bouck
Journal:  Cell       Date:  1998-06-26       Impact factor: 41.582

9.  Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model.

Authors:  M Corinna A Palanca-Wessels; Aloysius Klingelhutz; Brian J Reid; Thomas H Norwood; Kent E Opheim; Thomas G Paulson; Ziding Feng; Peter S Rabinovitch
Journal:  Carcinogenesis       Date:  2003-05-09       Impact factor: 4.944

10.  Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity.

Authors:  Carlo C Maley; Brian J Reid; Stephanie Forrest
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-08       Impact factor: 4.254

View more
  5 in total

1.  Squamous/epidermoid differentiation in normal breast and salivary gland tissues and their corresponding tumors originate from p63/K5/14-positive progenitor cells.

Authors:  Werner Boecker; Göran Stenman; Thomas Loening; Mattias K Andersson; Tobias Berg; Alina Lange; Agnes Bankfalvi; Vera Samoilova; Katharina Tiemann; Igor Buchwalow
Journal:  Virchows Arch       Date:  2014-10-26       Impact factor: 4.064

2.  Superficial esophageal lesions detected by endoscopic ultrasound enhanced with submucosal edema.

Authors:  Jian-Jun Li; Long-Jun He; Hong-Bo Shan; Thomas D Wang; Huan Xiong; Li-Ming Chen; Guo-Liang Xu; Xiao-Hai Li; Xin-Xin Huang; Guang-Yu Luo; Yin Li; Rong Zhang
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

Review 3.  Cell culture models for studying the development of Barrett's esophagus: a systematic review.

Authors:  P Bus; P D Siersema; J W P M van Baal
Journal:  Cell Oncol (Dordr)       Date:  2012-04-03       Impact factor: 6.730

4.  Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett's epithelium.

Authors:  Manisha Bajpai; Hana Aviv; Kiron M Das
Journal:  Mol Cytogenet       Date:  2012-11-29       Impact factor: 2.009

5.  The Role of Tumor Microenvironment in Chemoresistance: 3D Extracellular Matrices as Accomplices.

Authors:  Dimakatso Alice Senthebane; Tina Jonker; Arielle Rowe; Nicholas Ekow Thomford; Daniella Munro; Collet Dandara; Ambroise Wonkam; Dhirendra Govender; Bridget Calder; Nelson C Soares; Jonathan M Blackburn; M Iqbal Parker; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2018-09-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.